TY - JOUR
AU1 - Janssen, Bernd
AU2 - Schäfer, Bernd
AB - In 1906, Alois Alzheimer, a psychiatrist from Munich, Germany, described a new mental illness, which is a progressively damaging brain disorder, leading to neurodegeneration, erosion of basic intellectual functions along with histological changes, and ultimately the patient’s death. Up until now, and despite enormous efforts in academia and the pharmaceutical industry, there is only modest symptomatic treatment available, but no intervention at the roots of the disease. One of the contemporary active pharmaceutical ingredients applied for this purpose is galantamine, an amaryllidaceae alkaloid, found, e.g., in Galanthus nivalis. In 1960, its correct structure, an amino acid-derived tetracycle, has been established by Shigeru Kobayashi and Sir Derek Barton. Since then, a plethora of syntheses has been published. On industrial scale, galantamine is extracted from the bulbs of daffodils, though it can also be manufactured by total synthesis.
TI - Galantamine
JF - ChemTexts
DO - 10.1007/s40828-017-0043-y
DA - 2017-05-04
UR - https://www.deepdyve.com/lp/springer-journals/galantamine-mw97mcL8a3
SP - 1
EP - 21
VL - 3
IS - 2
DP - DeepDyve
ER -